# Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

> **NCT06705127** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- HR-positive,HER2-negative Breast Cancer

## Interventions

- **DRUG:** TORIPALIMAB INJECTION(JS001 )
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)

## Key facts

- **NCT ID:** NCT06705127
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06705127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06705127, "Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06705127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*